Saccharomyces boulardii in maintenance treatment of Crohn's disease

M. Guslandi, G. Mezzi, M. Sorghi, P. A. Testoni

Research output: Contribution to journalArticle

534 Citations (Scopus)

Abstract

The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI <150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.

Original languageEnglish
Pages (from-to)1462-1464
Number of pages3
JournalDigestive Diseases and Sciences
Volume45
Issue number7
DOIs
Publication statusPublished - 2000

Fingerprint

Mesalamine
Crohn Disease
Probiotics
Therapeutics
Intestines
Yeasts
Costs and Cost Analysis
Recurrence
Saccharomyces boulardii

Keywords

  • Crohn's disease
  • Mesalamine
  • Probiotics
  • Relapses
  • Saccharomyces boulardii

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Saccharomyces boulardii in maintenance treatment of Crohn's disease. / Guslandi, M.; Mezzi, G.; Sorghi, M.; Testoni, P. A.

In: Digestive Diseases and Sciences, Vol. 45, No. 7, 2000, p. 1462-1464.

Research output: Contribution to journalArticle

Guslandi, M. ; Mezzi, G. ; Sorghi, M. ; Testoni, P. A. / Saccharomyces boulardii in maintenance treatment of Crohn's disease. In: Digestive Diseases and Sciences. 2000 ; Vol. 45, No. 7. pp. 1462-1464.
@article{505dd1960f9342a3a8291f4dd8e20769,
title = "Saccharomyces boulardii in maintenance treatment of Crohn's disease",
abstract = "The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI <150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5{\%} of patients receiving mesalamine alone and in 6.25{\%} of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.",
keywords = "Crohn's disease, Mesalamine, Probiotics, Relapses, Saccharomyces boulardii",
author = "M. Guslandi and G. Mezzi and M. Sorghi and Testoni, {P. A.}",
year = "2000",
doi = "10.1023/A:1005588911207",
language = "English",
volume = "45",
pages = "1462--1464",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Saccharomyces boulardii in maintenance treatment of Crohn's disease

AU - Guslandi, M.

AU - Mezzi, G.

AU - Sorghi, M.

AU - Testoni, P. A.

PY - 2000

Y1 - 2000

N2 - The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI <150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.

AB - The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI <150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.

KW - Crohn's disease

KW - Mesalamine

KW - Probiotics

KW - Relapses

KW - Saccharomyces boulardii

UR - http://www.scopus.com/inward/record.url?scp=0033870413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033870413&partnerID=8YFLogxK

U2 - 10.1023/A:1005588911207

DO - 10.1023/A:1005588911207

M3 - Article

VL - 45

SP - 1462

EP - 1464

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 7

ER -